Showing results (1941-1950 of 2,232) with videos related to
Sort By:
Pageof 224
Cell Communication and Signaling : CCS|November 27, 2025
Immunosuppressants rewire the gut microbiome-alloimmune axis through time-dependent and tissue-specific mechanismsLong Wu, Allison Kensiski, Samuel J Gavzy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2015
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung CancerCaicun Zhou, Yi-Long Wu, Gongyan Chen, et al.BMC Cancer|July 5, 2017
A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)Qing Zhou, Yong Song, Xin Zhang, et al.The Oncologist|June 8, 2012
EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomasZhi-Yong Chen, Wen-Zhao Zhong, Xu-Chao Zhang, et al.The Journal of Clinical Investigation|May 1, 2025
CXCL12+ fibroblastic reticular cells in lymph nodes facilitate immune tolerance by regulating T cell-mediated alloimmunityYuta Yamamura, Gianmarco Sabiu, Jing Zhao, et al.Therapeutic Advances in Medical Oncology|November 25, 2022
An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)Shun Lu, Ying Cheng, Jianying Zhou, et al.Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trialsMartin Schuler, Luis Paz-Ares, Lecia V Sequist, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2023
Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final AnalysisChong Kin Liam, Azura Rozila Ahmad, Te-Chun Hsia, et al.Lung Cancer (Amsterdam, Netherlands)|March 8, 2025
Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA studyMarina Chiara Garassino, Yong He, Myung-Ju Ahn, et al.Journal of Hematology & Oncology|January 5, 2025
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)Hua-Jun Chen, Hai-Yan Tu, Yanping Hu, et al.Pageof 224